Holen Sie sich die Stockscreener-App
652.11
0.90%
-5.95
Handel nachbörslich:
652.11
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IDXX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$658.06
Offen:
$662
24-Stunden-Volumen:
491.85K
Relative Volume:
0.81
Marktkapitalisierung:
$52.17B
Einnahmen:
$4.04B
Nettoeinkommen (Verlust:
$985.66M
KGV:
54.30
EPS:
12.01
Netto-Cashflow:
$774.34M
1W Leistung:
-4.49%
1M Leistung:
+22.26%
6M Leistung:
+40.62%
1J Leistung:
+35.06%
1-Tages-Spanne:
$646.68
$665.52
1-Wochen-Bereich:
$623.40
$678.96
52-Wochen-Spanne:
$356.14
$688.12
Idexx Laboratories Inc Stock (IDXX) Company Profile
Firmenname
Idexx Laboratories Inc
Sektor
Branche
Telefon
(207) 556-0300
Adresse
ONE IDEXX DRIVE, WESTBROOK, ME
Vergleichen Sie IDXX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
652.11 | 52.65B | 4.04B | 985.66M | 774.34M | 12.01 |
|
TMO
Thermo Fisher Scientific Inc
|
462.39 | 173.97B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
199.76 | 143.61B | 24.01B | 3.41B | 4.86B | 4.70 |
|
A
Agilent Technologies Inc
|
114.13 | 32.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
180.09 | 30.58B | 15.50B | 1.33B | 2.16B | 7.34 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-05 | Bestätigt | BTIG Research | Buy |
| 2025-07-01 | Eingeleitet | Jefferies | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | BTIG Research | Buy |
| 2024-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2023-12-04 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2023-08-02 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-21 | Hochstufung | Goldman | Neutral → Buy |
| 2022-07-12 | Eingeleitet | Piper Sandler | Overweight |
| 2022-05-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-02-08 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-11-18 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-17 | Eingeleitet | Barclays | Overweight |
| 2019-09-09 | Eingeleitet | Goldman | Neutral |
| 2019-05-23 | Eingeleitet | Guggenheim | Buy |
| 2018-11-02 | Bestätigt | BofA/Merrill | Buy |
| 2018-05-07 | Bestätigt | Stifel | Buy |
| 2018-01-16 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-08-23 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | Hochstufung | CL King | Neutral → Buy |
| 2017-02-03 | Herabstufung | Feltl & Co. | Hold → Sell |
| 2016-09-29 | Fortgesetzt | BofA/Merrill | Neutral |
| 2016-08-16 | Bestätigt | Stifel | Buy |
| 2016-08-03 | Hochstufung | Northcoast | Sell → Neutral |
| 2016-07-20 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-19 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-01 | Eingeleitet | CL King | Neutral |
| 2016-03-21 | Bestätigt | Stifel | Buy |
| 2016-02-04 | Eingeleitet | Credit Suisse | Outperform |
| 2015-10-29 | Bestätigt | Stifel | Buy |
| 2015-08-28 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | Bestätigt | Stifel | Buy |
| 2015-07-23 | Bestätigt | Canaccord Genuity | Buy |
Alle ansehen
Idexx Laboratories Inc Aktie (IDXX) Neueste Nachrichten
A Closer Look at IDEXX Laboratories's Options Market Dynamics - Benzinga
IDEXX Laboratories (NASDAQ:IDXX) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat
IDEXX Laboratories Inc(IDXX.US) Officer Sells US$5.28 Million in Common Stock - 富途牛牛
IDEXX Labs Volume Plummets 28% as Veterinary Diagnostics Stock Slides to 256th in U.S. Trading Activity Rankings - AInvest
IDEXX Laboratories (NASDAQ:IDXX) Price Target Raised to $675.00 at JPMorgan Chase & Co. - MarketBeat
Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock - Yahoo Finance
How Idexx Laboratories Is Riding The 'Puppy Boom' To New Highs - MSN
IDEXX’s Healthy Streak Outpaces The Pack In Animal Care - Finimize
IDEXX Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Yahoo Finance
IDEXX Laboratories, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - simplywall.st
Decoding IDEXX Laboratories Inc (IDXX): A Strategic SWOT Insight - GuruFocus
Leerink Partners Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating, Raises Target Price to $745 - 富途牛牛
Why Idexx Laboratories (IDXX) is a Top Momentum Stock for the Long-Term - Yahoo Finance
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q2 2025 Earnings Call Transcript - Insider Monkey
Why a Company You’ve Never Heard of Is One of the Best Nasdaq-100 Stocks of the Year - inkl
IDEXX strengthens competitive edge in veterinary diagnostics - MarketScreener
IDEXX Laboratories stock price target raised to $785 from $625 at Jefferies - Investing.com India
Idexx Laboratories: Strong Financial Performance and Strategic Outlook Justify Buy Rating - TipRanks
IDEXX Executives Make Major Stock Trades on August 6 - AInvest
IDEXX Laboratories Reports Strong Q2 2025 Results - The Globe and Mail
IDEXX Laboratories’ Earnings Call Highlights Strong Growth - TipRanks
Is the Market Bullish or Bearish on IDEXX Laboratories? - 富途牛牛
A Quick Look at Today's Ratings for IDEXX Laboratories Inc(IDXX.US), With a Forecast Between $626 to $785 - 富途牛牛
Jefferies Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating, Raises Target Price to $785 - 富途牛牛
Tesla, Delta Air, IDEXX Laboratories And More On CNBC's 'Final Trades' - Benzinga
BNP Paribas Exane Adjusts PT on IDEXX Laboratories to $761 From $577, Maintains Outperform Rating - MarketScreener
Morgan Stanley Adjusts PT on IDEXX Laboratories to $722 From $626, Maintains Overweight Rating - MarketScreener
IDXX Surpasses Analyst Target Price of $558.30 - AInvest
Axon Enterprise, Berkshire Hathaway, Idexx Laboratories - TradingView
IDEXX Laboratories Inc (IDXX) Q2 2025 Earnings Call Highlights: Strong Revenue and EPS Growth ... - Yahoo Finance
IDEXX Laboratories Stock Price, Quotes and Forecasts | NASDAQ:IDXX - Benzinga
Idexx: Q2 Earnings Snapshot - Norwalk Hour
IDEXX Laboratories Inc (IDXX) Q2 2025 Earnings Call Highlights: Strong Revenue and EPS Growth ... By GuruFocus - Investing.com Canada
IDEXX Laboratories Soars: A New Benchmark for Animal Health Diagnostics - FinancialContent
IDEXX Laboratories' Price Target Raised to $675 by JP Morgan, Maintains Overweight Rating - AInvest
JPMorgan Boosts Idexx Laboratories' Price Target to $675, Maintains Overweight Rating - AInvest
BofA Boosts Price Target for Idexx Laboratories to $700 Amid Robust Q2 Performance - AInvest
IDEXX Laboratories Surges on Raised Revenue and Profit Forecasts, Analysts Mixed on One-Year Price Target - AInvest
Stifel Raises Idexx Laboratories Price Target to $640, Keeps Hold Rating - AInvest
Research Alert: CFRA Maintains Buy Opinion On Shares Of Idexx Laboratories, Inc. - 富途牛牛
IDEXX Laboratories Surges on Price Target Adjustments and New Board Member - timothysykes.com
Log Commercial 2Q net revenue R$61.5M, estimate R$60.3M - AInvest
IDEXX Labs Stock Sparks Interest: Analyzing Market Buzz - timothysykes.com
IDEXX LABORATORIES INC /DE SEC 10-Q Report - TradingView
U.S. Indexes Moved Upward Monday; IDEXX Laboratories Led Increases - Barron's
How A 'Puppy Boom' Drove This Company's Beat-And-Raise - Investor's Business Daily
IDEXX Laboratories Stock: Ready for a Breakout? - StocksToTrade
Idexx's Innovation Is on Display with Introduction of InVue Platform - Morningstar
IDEXX Laboratories (IDXX) Boosts 2025 Earnings and Revenue Forecasts - GuruFocus
Is Now a Good Time to Reenter IDEXX Laboratories Inc.Low Risk High Return Opportunities Identified - metal.it
IDEXX Surge: Time to Dive In? - timothysykes.com
Finanzdaten der Idexx Laboratories Inc-Aktie (IDXX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.43%
0.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):